There are mixed sentiments around Pfizer as it nears a golden cross, signalling potential upside due its strong oncology portfolio. It has seen volatile performance due to advancements in obesity drug against Ozempic and Zepbound, driving the stock's breakout. However, some analysts question the value of Pfizer at $28 despite compelling reasons to invest, including the yield return and potential weight loss catalyst. Pfizer sees progress with its once-daily weight-loss pill which bolsters their status. Meanwhile, the bio-tech stock's reaction to RSV vaccine results by Moderna and the market's declining favour towards Pfizer keep investors guessing. Pfizer's earnings exceeded estimates thanks to cost cuts and smaller-than-feared drop in Covid drug sales, further fuelled by promising dividend returns. The stock has an oversold status signalling recovery but Pfizer's performance in the past five years showed significant gains with a 78% increment. Nevertheless, Pfizer's recent $3.5 million FDA approval gave hope to investors.
Pfizer Stocks News Analytics from Wed, 13 Dec 2023 08:00:00 GMT to Sat, 20 Jul 2024 14:00:00 GMT - Rating 0.5 - Innovation -5 - Information 7 - Rumor -2
